Upadacitinib produced by Lao Big Bear Pharmaceutical Company, as a legal generic version of the originator upadacitinib, provides a more cost-controllable JAK inhibitor treatment option for patients worldwide.
Is there a Lao generic version of Upadacitinib?
Yes, there is a Lao generic version of upadacitinib. The Lao Big Bear version of upadacitinib is available in the specification of 15mg*30 tablets/box. For more information, we recommend you contact professional customer service for detailed consultation.
Indications of Upadacitinib
In October 2019, biopharmaceutical giant AbbVie announced important news: the U.S. Food and Drug Administration (FDA) has officially approved the marketing of its developed JAK1 inhibitor upadacitinib. The drug is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR). This approval marks the addition of a potent oral targeted therapy option in the field of RA treatment. Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized mainly by synovial inflammation and hyperplasia of the joints, leading to joint pain, swelling, stiffness, and even irreversible joint destruction. Although methotrexate is the traditional first-line treatment, a considerable proportion of patients have a poor response to it or cannot tolerate its side effects. Upadacitinib, as a once-daily oral small molecule drug, provides a convenient and highly effective new treatment option for these patients. This FDA approval was based on data from multiple pivotal Phase III clinical studies, which confirmed the significant efficacy of upadacitinib in improving RA symptoms, signs, and physical function. AbbVie stated that the launch of upadacitinib will address unmet medical needs in RA treatment, especially for patients who have failed treatment with conventional synthetic disease-modifying antirheumatic drugs.
Mechanism of Action of Upadacitinib
The active pharmaceutical ingredient of upadacitinib is upadacitinib, an oral selective JAK1 inhibitor discovered and developed by AbbVie. The JAK (Janus kinase) family is a group of intracellular non-receptor tyrosine kinases that play a critical role in the signal transduction of various cytokines. Specifically, JAK1 is a kinase that plays a central role in the pathophysiology of many inflammatory diseases. By selectively inhibiting JAK1, upadacitinib interferes with the JAK-STAT signaling pathway, effectively blocking the signal transmission of multiple inflammation-related cytokines (such as IL-6, IL-2, IFN-γ, etc.), thereby modulating immune responses and reducing inflammatory damage in joints and throughout the body. Compared with first-generation pan-JAK inhibitors, upadacitinib has higher selectivity for JAK1, which theoretically may provide a better balance of efficacy and safety. Currently, in addition to the already approved indication for moderately to severely active rheumatoid arthritis, upadacitinib is being studied in Phase III clinical trials for a broad range of immune-mediated diseases, including psoriatic arthritis (PsA), Crohn's disease (CD), atopic dermatitis (AD), and ulcerative colitis (UC). Furthermore, the drug is also being evaluated for the treatment of ankylosing spondylitis. This series of research and development layouts fully demonstrates the broad therapeutic potential of the JAK1 target in various autoimmune and inflammatory diseases.
